Consun Pharmaceutical Group Ltd. has announced a share repurchase program under the Repurchase Mandate, with an aggregate amount of capital available for the proposed share repurchase up to HKD200 million. The company will repurchase shares from the open market from 13 June 2025 until the conclusion of the next annual general meeting.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.